Sonnet BioTherapeutics Holdings
Stock Forecast, Prediction & Price Target

	Passed			Analyst forecast
Metric	9/30/2022	9/30/2023	9/30/2024	9/30/2026	9/30/2027
Revenue % change YoY	$349.94K N/A	$147.80K -57.76%	$18.62K -87.39%	Avg: $22.82K Low: $22.82K High: $22.82K avg. 22.52%	Avg: $12.24K Low: $12.24K High: $12.24K avg. -46.35%
Net Income % change YoY	$-29.77M N/A	$-18.83M 36.74%	$-7.43M 60.50%	Avg: $-28M Low: $-12.79M High: $-12.79M avg. -276.48%	Avg: $-12.56M Low: $-12.56M High: $-12.56M avg. 55.13%
EBITDA % change YoY	$-29.61M N/A	$-18.71M 36.80%	$-11.84M 36.69%	Avg: $-9.65K Low: $-9.65K High: $-9.65K avg. 99.91%	Avg: $-5.18K Low: $-5.18K High: $-5.18K avg. 46.34%
EPS % change YoY	-$150.79 N/A	-$18.14 87.97%	-$11.35 37.43%	Avg: -$12.32 Low: -$12.32 High: -$12.32 avg. -8.54%	Avg: -$12.1 Low: -$12.1 High: -$12.1 avg. 1.78%
Operating Expenses % change YoY	$30.01M N/A	$18.94M -36.90%	$11.86M -37.33%	Avg: $421.08K Low: $421.08K High: $421.08K avg. -96.45%	Avg: $225.91K Low: $225.91K High: $225.91K avg. -46.35%

FAQ

Wall Street analysts estimate the annual average earnings growth rate of -110.67% in 2026-2027.

We have gathered data from N/A analysts. Their low estimate is -12.79M, average is -28M and high is -12.79M.

Wall Street analysts forecast annual average revenue growth of -11.91% in 2026-2027.

We have gathered data from 1 analysts. Their low revenue estimate is $22.82K, average is $22.82K and high is $22.82K.

Wall Street analysts forecast annual average earnings growth of -3.38% in 2026-2027.

We have gathered data from N/A analysts. Their low earnings per share estimate is -$12.32, average is -$12.32 and high is $-12.32.